WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006114312) VACCINE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/114312    International Application No.:    PCT/EP2006/003918
Publication Date: 02.11.2006 International Filing Date: 24.04.2006
IPC:
A61K 39/12 (2006.01)
Applicants: GLAXOSMITHKLINE BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE) (For All Designated States Except US).
COLAU, Brigitte, Desiree, Alberte [BE/BE]; (BE) (For US Only)
Inventors: COLAU, Brigitte, Desiree, Alberte; (BE)
Agent: STEPHEN, Robert; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB)
Priority Data:
60/674,829 26.04.2005 US
0509010.5 03.05.2005 GB
PCT/EP2005/006461 14.06.2005 EP
Title (EN) VACCINE
(FR) VACCIN
Abstract: front page image
(EN)A method for prevention of HPV infection and/or disease, the method comprising delivery of a first HPV vaccine comprising an L1 protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 L1 components from the first vaccine, and which second vaccine comprises an L1 protein or immunogenic fragment thereof from at least one other oncogenic HPV type, wherein the first and second vaccines may be delivered in either order and delivery is separated by a suitable time interval.
(FR)L'invention concerne une méthode destinée à prévenir une infection à VPH et/ou une maladie liée au VPH, et consistant à administrer un premier vaccin anti-VPH renfermant un fragment immunogène ou de protéine L1 correspondant obtenu au moins à partir de VPH 16 et VPH 18, et un second vaccin anti-VPH ne comprenant pas les constituants L1 de VPH 16 et VPH 18 obtenu à partir du premier vaccin, ce second vaccin renfermant un fragment immunogène ou de protéine L1 correspondant obtenu à partir d'au moins un autre type de VPH oncogène, lesdits premier et second vaccins pouvant être administrés dans n'importe quel ordre, les administrations étant séparées par un intervalle de temps approprié.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)